GLPwatch
Wegovy for Alzheimer's disease
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for Alzheimer's disease, and its use for this condition is off-label/investigational. A study using nationwide real-world data in the US found associations between semaglutide and first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Alzheimer's disease |
| Approval status | Investigational / off-label |
| Research papers | 29 |
Wegovy is not FDA-approved for alzheimer's disease; the research below reflects investigational or off-label study only.
Research on semaglutide for alzheimer's disease (29)
- Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.
- evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
- Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
- Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice.
- Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.
- Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.
- A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies.
- The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice.
- Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.
- Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.
- The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy/ACE2/SIRT1/FOXO1-Mediated Microglia Polarization.
- Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
- Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.
- Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.
- A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.
- Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.
- Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.
- Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.
- Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.
- Transcriptomics and proteomics characterizing the antioxidant mechanisms of semaglutide in diabetic mice with cognitive impairment.
- Semaglutide attenuates Alzheimer's disease model progression by targeting microglial NLRP3 inflammasome-mediated neuroinflammation and ferroptosis.
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model.
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.